• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Methyltransferase Assay Kits
      • Ligase and Synthetase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • AMPK Assay Kits
      • cGAS Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • TBK1 Assay Kits
    • Recombinant cGAS Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • OAS1 Assay Services
  • Innate Immunity
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD39 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

New Publication: HTS Method for Measuring Drug Residence Time

by Bellbrook Labs / Tuesday, 25 April 2017 / Published in Company, HTS Assays, News

View our latest publication, “A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener® ADP2 Assay” in SLAS Discovery.

Inhibitor residence times are increasingly being used to prioritize molecules early in lead discovery programs. Current methods for determining residence time are low-throughput or require the synthesis of labeled ligands. Our goal was to create an HTS compatible assay method that was broadly applicable to protein kinases.  Senior Application Scientist, Meera Kumar, used the “jump dilution” kinetic approach with the Transcreener® ADP Kinase Assay to estimate residence times by continuously monitoring kinase enzymatic activity as inhibitors dissociated. The ability to determine residence times in an HTS format opens the door to characterizing more compounds earlier in discovery.

Drug Residence Time Examples

Residence Times of Inhibitors for ABLI Measured Using the Transcreener® ADP Kinase Assay

Residence time, the time that an inhibitor is bound to a target, is the reciprocal of the dissociation rate (1/koff). Here, we demonstrated residence time measurements for a number of known inhibitors for EGFR, ABLI, and Aurora kinases.  In the study, the rank order of koff values correlated well with published values, but some absolute values were quite different, most likely due to differences inherent in the methods. We also showed similar results between the three fluorescent detection readouts (FP, FI, and TR-FRET) available with the Transcreener® ADP2 Kinase Assay. The data validates the assay method as a universal approach for estimating drug residence times with the ability to use a variety of fluorescent readouts in an HTS format.

To learn more, please read the full publication.

Read Our Residence Time Application Note

Tagged under: Assay Development Services, drug discovery services, Lead Discovery Services, Residence Time, Transcreener ADP Kinase Assay, Transcreener AMP/GMP Assay, Transcreener GDP Assay, Transcreener UDP Assay

What you can read next

BellBrook Labs sells Drug Discovery Kits to Major Pharmaceutical Clients.
BELLBROOK LABS RECEIVES KEY PATENT PROTECTION FOR NOVEL DRUG DISCOVERY PLATFORM
BellBrook Labs Introduces the Transcreener™ TR-FRET Kinase Assay

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Researcher Using An ADP Assay

    Accelerating Discovery of Kinase Inhibitors Using an ADP Assay

    An ADP assay can be used to study the activity ...
  • Inhibitors of ENPP1 SLAS Discovery

    New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1

    BellBrook scientist Meera Kumar and Robert Lowe...
  • GMP Assay for PDE Inhibitor Discovery

    Using a Universal GMP Assay for PDE Research

    A universal GMP assay to aid in PDE research an...
  • SLAS 2021

    Join Us for SLAS 2021 Virtual Conference

    BellBrook Labs will be exhibiting at SLAS 2021,...
  • New cGAS TR-FRET Assay

    New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

    Launched in November 2019, the Transcreener cGA...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2019 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP